A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Must have received:

ccRCC: ≥1 prior line incl. ICI + TKI

Must have received:

DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage

Must have received:

PTCL/CTCL: ≥1 prior systemic therapy

Cannot have received: CD70-targeting therapy

Prior CD70-targeting therapy, including CAR T

Cannot have received: CAR-T cell therapy

Exception: ≤12 weeks before enrollment

CAR T ≤12 weeks before enrollment

Cannot have received: autologous stem cell transplant

Exception: ≤12 weeks before enrollment

ASCT ≤12 weeks before enrollment

Cannot have received: organ transplant

prior organ or allogeneic transplant

Cannot have received: allogeneic transplant

prior organ or allogeneic transplant